Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy

RegulatoryapprovedJaypirca®Positive

AI Analysis

Summary

Innovent Biologics announced approval of Jaypirca (pirtobrutinib) in China for chronic lymphocytic leukemia and small lymphocytic lymphoma across all lines of therapy, marking a significant regulatory milestone for the BTK inhibitor in the Asia-Pacific region.

Outcome Details

Approved in China for Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) across all lines of therapy

Importance:7/10

Sentiment:

0.85

regulatory approvalChinaoncologyhematologic malignancyBTK inhibitor

Related Companies

$DFPH $CHHE $WHEN

Read the original article

Published by PR Newswire Biotech on September 28, 2026 10:30 AM

Read Original